(ACR14) (VIDEO) In tests so far, the infliximab biosimilar BOW015, just approved in India, seems to look about the same to the human immune system as the original. Here, a VP of the company behind BOW015 talks about the realities of seeking approval in the US.
(ACR2014) (VIDEO) The National Institutes of Health's PROMIS measures, created to study health status in the general population, look good for meaningful outcomes assessment in diseases such as rheumatoid arthritis, says an expert who studies measurement of disability in rheumatic disorders..
(VIDEO) Researchers in Norway used data from an observational study of patients with swollen joints to see how many with early signs of rheumatoid arthritis recovered without any treatment at all, and how quickly.
In the second installment of a slide show based on an animated discussion by members of the rheumatology journal club (#rheumjc), partipants focus on the benefits, risks, and realities of tapering biologics in clinical practice.
Slides present key points from a Twitter-based journal club, pondering a randomized study of tapering TNF inhibitors in rheumatoid arthritis. Many questions about the study design. More ask about practices already in use (addressed in Part 2).
In the third edition of #rheumjc, author (and Twitter regular) John Cush MD discusses a report from a summit on management of pregnancy and lactation in women with autoimmune and inflammatory diseases.
Lupus is the condition that most frequently requires attention to skin problems, but it's far from the only reason for a rheumatologist's patient to see a dermatologist. In the case of lupus, however, the lesion may be a clue to prognosis.